Growing epilepsy and restless legs syndrome is expected to drive the growth of India Gabapentin market during the forecast period.
According to TechSci Research report, “India Gabapentin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule, Others), By Strength (100 mg, 200 mg, 300 mg, 400 mg, Others), By Distribution Channel (Online v/s Offline), By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome (RLS), Seizures, Others), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, the India Gabapentin market is expected to grow at a steady rate during the forecast period. The medication is very effective in treating hot flashes as well as neuropathic pain.
Moreover, it is considered as first line medication for treating neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain which is expected to fuel the market growth through FY2026. Furthermore, Gabapentin is approved for treatment of focal seizures as well as mixed seizures, thereby projected to bode well for the market growth in the next 5 years.
However, side-effects associated with drug consumption such as sleepiness and dizziness can restrict the market growth over the next few years. Moreover, in some severe cases, side effects such as increased risk of suicide, aggressive behavior, and drug reactions can occur. This can further reduce the usage and application of the drug thereby hindering the market growth during the forecast period.
Browse XX market data Tables and XX Figures spread through XX Pages and an in-depth TOC on “India Gabapentin Market “
https://www.techsciresearch.com/report/india-gabapentin-market/5163.html
The India gabapentin market is segmented based on source, form, strength, distribution channel, application, end user, company, and region. Based on end user, the market can be fragmented into adult v/s pediatric. The adult segment dominated the market until 2017 and is further forecasted to maintain its dominance during the forecast period as well. This dominance can be accredited to the wide use of Gabapentin in adults to treat nerve pain caused by herpes virus or shingles.
The pediatric segment is expected to grow at a high CAGR in the market during forthcoming years on account of rising use of this drug for treating RLS in children. Based on source, the market can be categorized into in-house v/s contract manufacturing organizations. The in-house segment dominated the market until 2017 as most of the leading companies focus on in house production owing to high standardization and flexibility. Contract manufacturing organizations segment is expected to witness significant growth in the market as it saves cost and maximize profits.
Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Alkem Laboratories Ltd., Intas Pharmaceuticals Ltd., Hetero Drugs Ltd., Silverline Chemicals Ltd., Taj Pharmaceuticals Ltd., Divis Laboratories Ltd., Unnati Pharmaceuticals Pvt. Ltd. and others are some of the leading players operating in India gabapentin market. Companies operating in the market are using strategies such as joint ventures, product launches, mergers and research collaborations to boost their share and increase their geographic reach.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5163
Customers can also request for 10% free customization on this report.
“India gabapentin market is expected to witness growth during the forecast period as it is used to treat patients with restless legs syndrome (RLS). In addition to this, Gabapentin medications also prescribed for many off-label uses, including treatment of anxiety disorders, bipolar disorder and insomnia. This is further expected to create lucrative opportunities for the market growth of India gabapentin market over the next five years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.
“India Gabapentin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule, Others), By Strength (100 mg, 200 mg, 300 mg, 400 mg, Others), By Distribution Channel (Online v/s Offline), By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome (RLS), Seizures, Others), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India gabapentin market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India gabapentin market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]